# Osaka Red Cross Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/osaka-red-cross-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 103 |
| Citations | 102,968 |
| City | Osaka |
| Country | JP |
| Description | Osaka Red Cross Hospital is a research organisation in Osaka, JP. OpenAlex records 2,714 works and 102,968 citations for it. 588 researchers list it as their most recent affiliation. |
| Homepage | http://www.osaka-med.jrc.or.jp/ |
| OpenAlex ID | https://openalex.org/I4210151887 |
| Researchers | 588 |
| ROR ID | https://ror.org/05h4q5j46 |
| Type | healthcare |
| Works | 2,714 |

## University papers

Showing 12 of 22.

- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)](https://scholariq.org/papers/biomarker-analyses-and-final-overall-survival-results-from-a-phase-iii/)
- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-i-her2-i-mutant-non-small-cell-lung-cancer/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan](https://scholariq.org/papers/randomized-phase-iii-study-of-cisplatin-plus-irinotecan-versus-carboplatin-plus/)
- [CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study](https://scholariq.org/papers/ch5424802-ro5424802-for-patients-with-alk-rearranged-advanced-non-small-cell/)
- [Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-randomized-trial-of-ipilimumab-plus-etoposide-and-platinum-versus/)
- [Interstitial Lung Disease in Japanese Patients with Lung Cancer](https://scholariq.org/papers/interstitial-lung-disease-in-japanese-patients-with-lung-cancer/)
- [Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations](https://scholariq.org/papers/improvement-in-overall-survival-in-a-randomized-study-that-compared-dacomitinib/)

## University top topics

Showing 8 of 25.

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Blood groups and transfusion](https://scholariq.org/topics/blood-groups-and-transfusion/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Erythrocyte Function and Pathophysiology](https://scholariq.org/topics/erythrocyte-function-and-pathophysiology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.